The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Epcoritamab plus R-miniCVP for newly diagnosed DLBCL: insights from a Phase II trial
Dai Chihara, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares findings from a single-arm Phase II trial (NCT06045247) evaluating the combination of epcoritamab with rituximab (R)-mini cyclophosphamide, vincristine, and prednisone (CVP) for older, unfit, or frail patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who may be unable to tolerate full intensity anthracycline-based chemotherapy. Dr Chihara notes that the treatment was well tolerated, with all patients completing six cycles, and highlights favorable complete response (CR) and one-year progression-free survival (PFS) rates. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We conducted a single-arm Phase II trial evaluating epcoritamab in combination with our R-mini-CVP, like low-intensity chemotherapy for patients with older unfit, frail or anthracycline-ineligible patients with newly diagnosed diffuse large B-cell lymphoma at MD Anderson Cancer Center. This was an investigator-initiated study with a single arm. The trial is still in progress...
We conducted a single-arm Phase II trial evaluating epcoritamab in combination with our R-mini-CVP, like low-intensity chemotherapy for patients with older unfit, frail or anthracycline-ineligible patients with newly diagnosed diffuse large B-cell lymphoma at MD Anderson Cancer Center. This was an investigator-initiated study with a single arm. The trial is still in progress. We are planning to enroll 40 patients, but at this meeting, we reported the first 26 patients who completed six cycles of the treatment. So the treatment is a combination of epcoritamab with R-mini-CVP. Patients first received one cycle of R-mini-CVP for debulking to mitigate the CRS. Epcoritamab was introduced from cycle two and then patients completed the treatment of the combination through cycle six. The toxicity was very favorable. All patients completed six cycles of treatment. It was very well tolerated. And then the complete response rate after six cycles was 88%. And even though the median follow-up is still short, it’s approximately one year, but a one-year progression-free survival was very encouraging with 89% at one year.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
